Log In
Print
BCIQ
Print
Print this Print this
 

Keppra, levetiracetam

Also known as: Keppra (IV)

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionHigh affinity synaptic vesicle protein (SV2A) ligand for intravenous administration
Molecular Target Synaptic vesicle protein (SV2A)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationSeizures
Indication DetailsTreat partial onset seizures in adult patients with epilepsy; Treat partial-onset seizures in adults with epilepsy when oral administration is temporarily not feasible
Regulatory Designation
Partner Otsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$684.1M

$684.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today